Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis
Abstract Introduction In pooled LIBERTY-PN PRIME/PRIME2 trials on prurigo nodularis (PN), at week 24, the stringent composite endpoint of a ≥ 4-point reduction from baseline in Worst Itch Numeric Rating Scale (WI-NRS) score combined with an Investigator’s Global Assessment for PN-Stage (IGA PN-S) sc...
שמור ב:
| Principais autores: | , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Adis, Springer Healthcare
2026-05-01
|
| סדרה: | Dermatology and Therapy |
| נושאים: | |
| גישה מקוונת: | https://doi.org/10.1007/s13555-026-01777-z |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
